Latest Biotech News

Tempus AI and Northwestern University's Abrams Research Center are collaborating to apply AI-driven data analytics to genomic data focused on Alzheimer's disease. Using Tempus’ Lens platform, the...

BioNTech has agreed to acquire CureVac in an all-stock deal valued around $1.25 billion, marking a strategic expansion of its mRNA platforms for cancer immunotherapy. The acquisition focuses...

SpliceBio has secured $135 million in Series B financing to complete clinical development of SB-007, a dual AAV vector gene therapy for Stargardt’s disease, a leading inherited retinal disorder...

MaxCyte and Ori Biotech have entered a strategic collaboration to enhance manufacturing efficiency and scalability for autologous cellular therapies. The partnership combines MaxCyte’s...

Researchers have developed an instantaneous brain-to-voice neuroprosthesis allowing a man with amyotrophic lateral sclerosis (ALS) to communicate using synthesized speech reproducing his own...

Enduro Genetics reports a pioneering synthetic biology approach that counters cellular micro-evolution during monoclonal antibody (mAb) manufacturing. By harnessing biosensors and regulatory...

Bristol Myers Squibb’s RayzeBio unit licensed exclusive global rights to Philochem's OncoACP3, a prostate cancer-targeting diagnostic and radiopharmaceutical therapeutic candidate, via a $350...

Eli Lilly has partnered with Juvena Therapeutics in a deal featuring upfront payments and milestones exceeding $650 million to develop muscle health drugs. Juvena’s AI-driven platform maps...

Merck received FDA approval for Enflonsia (cesrovimab), a long-acting monoclonal antibody to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in newborns and...

BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating their positions in mRNA-based cancer immunotherapies and vaccines. This strategic move aims to...

SpliceBio secured $135 million to advance its dual AAV gene therapy targeting Stargardt disease, a significant step for treating inherited retinal disorders. The financing bolsters clinical...

Genentech announced workforce reductions of 143 roles at its South San Francisco headquarters as part of efforts to streamline operations. The layoffs follow prior cuts and organizational changes,...

BioNTech announced plans to acquire CureVac for $1.25 billion in an all-stock deal, consolidating two mRNA-focused biotechs. This acquisition enhances BioNTech's pipeline in cancer immunotherapy...

The FDA has conferred a platform technology designation to Sarepta Therapeutics, aiming to streamline regulatory reviews for gene therapies the company may develop. This status is part of FDA...

Schrödinger reported preliminary safety and efficacy signals from an ongoing Phase 1 trial evaluating its MALT1 inhibitor. The findings reinforce the utility of the company's computational drug...

Nuvation Bio received FDA approval for Ibtrozi (taletrectinib), targeting advanced ROS1-positive non-small cell lung cancer. Approval was based on robust response rates reported in multiple...

Bristol Myers Squibb, through its RayzeBio subsidiary, acquired global rights to Philochem AG’s OncoACP3, a radiopharmaceutical candidate for prostate cancer, with a $350 million upfront payment...

SpliceBio secured $135 million in Series B funding to support clinical development of its lead gene therapy candidate, SB-007, for Stargardt disease. The dual AAV vector therapy aims to deliver...

Researchers have advanced RNA-targeting CRISPR-Cas13 technology to enable selective modification of desired RNA sequences in living cells. This next-generation gene therapy approach shows promise...

Insilico Medicine launched Nach01, a multimodal foundation AI model on AWS Marketplace designed to accelerate generative chemistry for drug design. This large language model integrated with...